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KEY POINTS
 Normal triiodothyronine (T3) levels are essential to preserve cardiac morphology and function.
 Overt and subclinical hypothyroidism are associated with an increased risk of heart failure, and lev-
othyroxine is able to improve cardiovascular function in hypothyroid patients.
 Low T3 syndrome can develop in patients with advanced heart failure and is associated with a
negative prognosis.
 Low T3 syndrome is associated with alterations in thyroid hormone receptors expression, contrib-
uting to the development of a cardiac fetal phenotype, leading to cardiac dysfunction.
 The positive effects of treatment with thyroid hormones in patients with low T3 and heart failure sup-
port their potential therapeutic approach in heart failure..c
omINTRODUCTION
It is widely recognized that thyroid hormone (TH)
excess (overt hyperthyroidism and subclinical hy-
perthyroidism) and TH deficiency (overt hypothy-
roidism and subclinical hypothyroidism [SHypo])
can represent potential causes of the onset or
worsening of heart failure (HF).1–3 Moreover,
changes in thyroid function can develop in acute
and chronic illnesses (nonthyroidal illnesses),
including HF.4,5
CELLULAR MECHANISMS OF THYROID
HORMONE ACTION ON THE HEART
Triiodothyronine (T3), the active TH, affects heart
rate, cardiac contractility, and systemic vascular
resistance (SVR).1,4,5 The physiologic effects of
T3 on the cardiovascular (CV) system are in
part mediated by genomic mechanisms, which
result from the binding of T3 to nuclear THDisclosure Statement: The author has nothing to disclose
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abundant in the human atria and ventricles, regu-
late the transcription of various cardiac genes
expression, ion channels, and cell surface recep-
tors. The transcriptions of a–myosin heavy chain
(MHC) isoform, sarcoplasmic reticulum Ca21-
adenosine triphosphatase ATPase (SERCA2),
voltage-gated K1 channels, b1-adrenergic recep-
tors, guanine nucleotide regulatory proteins,
adenylate cyclase, NA1/K1-ATPase, atrial brain
natriuretic peptide (BNP), and malic enzyme are
up-regulated by T3.1,4,5 On the contrary, the ex-
pressions of b-MHC, phospholamban, Na1/
Ca21 exchanger, TR-a1, and adenylyl cyclase
types V and VI are down-regulated by T3.1,4,5
Nongenomic TH actions, which do not involve
TR-mediated transcriptional events, are more
rapid than genomic effects; they control the ef-
fects of T3 on the transport of glucose and amino
acids and ion fluxes across the plasma.
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Biondi394membrane; they also regulate the cytoskeleton
and mitochondrial functions.4,6
Altogether, these direct and indirect effects of
TH are important in regulating the cardiac rhythm
and CV hemodynamic. Genomic and nongenomic
TH actions control the cardiac pacemaker and
heart rate, the potential duration and repolarization
currents, the response to b-adrenergic receptor,
and the interaction with other neurohormonal fac-
tors.1,4,7 Moreover, T3 administration is able to
improve the CV hemodynamic by influencing
the relaxation and contractile properties of the
myocardium and by acting on the cardiac preload
and afterload.1,7 Cardiac volume is increased by
T3 administration for the activation of the renin-
angiotensin-aldosterone system (RASS); on the
contrary, cardiac afterload is reduced because of
the T3 effects on the vascular tone.4 T3 reduces
SVR and increases nitric oxide availability,
improving endothelial function.4,5THYROID DYSFUNCTION AND HEART
FAILURE
Overt hypothyroidism (characterized by increased
serum thyrotropin [TSH] and reduced free T3 and
free thyroxine levels) is associated with left ventric-
ular diastolic dysfunction.8 The activity of the
Ca21-ATPase within the sarcoplasmic reticulum
is decreased, with a consequent reduced reuptake
of calcium during diastole.7,8 Moreover, both sys-
tolic and diastolic functions are impaired during
effort, leading to an decreased exercise tolerance
for the slowed myocardial relaxation and the
impaired left ventricular filling and vasodilatation
during effort.9,10 The onset of dyspnea during ex-
ercise can be the first symptom of the altered CV
hemodynamic in patients with TH deficiency.9,10
CV findings, similar to overt hypothyroidism, also
have been reported in patients with SHypo, a con-
dition characterized by increased serum TSH with
levels of THs within the reference range, although
at their lower limits.2,3 Several studies using
Doppler echocardiography, tissue Doppler, and
cardiac MRI suggest that patients with mild TH
deficiency or severe TH deficiency can have CV al-
terations, leading to a higher risk of developing HF
when TH deficiency is untreated in the long-
term.2,3,9–14 Moreover, SHypo can be a risk factor
for cardiac death in patients with chronic HF.15
Treatment of overt hypothyroidism and SHypo
with levothyroxine (LT4) is able to prevent the pro-
gressive left ventricle dysfunction and improve
systolic and diastolic dysfunctions, SVR, and endo-
thelial function, improve cardiac output thereby
increasing (CO) and stroke volume.11,12,16 There-
fore, LT4 in replacement doses is recommendedby international guidelines and expert opinions in
patients with serum TSH above 10 mU/L.2,3,17,18
This treatment also should be considered when
serum TSH is persistently increased in mild disease
(TSH 4.5–9.9 mU/L), especially in patients with a
high CV background.2,3,17,18THYROID ABNORMALITIES IN
NONTHYROIDAL ILLNESS SYNDROME
Nonthyroidal illness syndrome (NTIS) is character-
ized by decreased serum T3 levels, normal to
high levels of reverse T3 (rT3), and inappropriately
normal serum TSH or low serum TSH.19–21 This
syndrome can be considered a neuroendocrine
response to a severe illness or starvation. Initial ab-
normalities of NTIS are characterized by decreased
serum T3 and increased rT3 levels.19,20 The patho-
physiologic basis of the development of these al-
terations are related to the following effects: (1) a
decreased extrathyroidal conversion of thyroxin
(T4) to T3 for the reduced activity of type 2 deiodi-
nase, (2) a decreased transport of T4, and (3) an
increased TH catabolism for the enhanced activity
of type 3 deiodinase (D3) in the peripheral tis-
sues.19–22 rT3 is consequently increased due to
its reduced peripheral catabolism and clearance.
TSH levels may rise briefly after the onset of the
acute disease; however, circulating TSH levels usu-
ally remain within the low to normal range. Subse-
quently, TSH can be decreased as a consequence
of a central hypothyroidism due to a reduced serum
TSH secretion for abnormalities in thyrotropin-
releasing hormone secretion and clearance. The
progressive development of a low serum T4 is
linked to an increased probability of death.19–22
Low levels of T3 are associated with a
decreased metabolic rate. Therefore, the changes
in TH homeostasis during the acute phase of NTIS
have been interpreted as an attempt to save en-
ergy expenditure and do not require any interven-
tion. This interpretation of the low T3 syndrome,
however, remains controversial and has been
debated for many years probably because it may
have a different significance in the acute and
chronic phases of illness.21
Experts suggest that serum TSH and T3 levels
should be reassessed within 1 months to 3 months
after an acute illness before deciding to start a
treatment with replacement doses of TH.17,19–22THYROID ABNORMALITIES IN HEART
FAILURE
HF represents a common final condition of severe
cardiac diseases.23
Table 1
Main findings in heart failure and effects of
low T3 syndrome on the cardiovascular system
Heart
Failure
Heart Failure
D Low T3
Syndrome
LV systolic function Y Y Y
LV diastolic function Y Y Y
SVR [ [ [
Cardiac contractility Y Y Y
Renal function Y Y Y
CO Y Y Y
Alterations in the
myocyte shape
[ [ [
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by a decreased CO, increased atrial pressure, and
inadequate blood volume, which is compensated
by the activation of the RAAS and systemic nervous
system to preserve blood volume and pressure. A
low T3 syndrome can develop in this phase of HF;
it could represent an adaptive process to reduce
energy expenditure andmetabolic demand. Subse-
quently, the progression of HF is characterized by a
persistent neuroendocrine activation, which is asso-
ciated with an increase in hormonal response
(enhanced levels of RAAS, vasopressin, cortisol, in-
sulin, atrial natriuretic peptide, and BNP and
reduced levels of growth hormone) and in inflamma-
tory and immunologicmediators (cytokines, such as
interleukin 6 and tumor necrosis factor). All these
changes are responsible for an increased cardiac
overload and myocardial fibrosis with a negative
cardiac remodeling and a progressive deterioration
and apoptosis of myocytes and endothelial func-
tion. In this advanced stage of HF, the administra-
tion of b-adrenergic blocking drugs, digitalis,
angiotensin-converting enzyme inhibitors, diuretics,
and aldosterone antagonists can improve symp-
toms and CO. Morbidity, mortality, and recurrent
hospitalization, however, are always high in patients
with advanced HF for the progressive and irrevers-
ible cachexia.23 Therefore, the persistent activation
of the hormonal and inflammatory system and the
persistent low T3 syndrome represent a maladap-
tive mechanism inducing cellular, functional, and
morphologic negative CV changes with a negative
cardiac remodeling. All these factors are respon-
sible for the progression of HF and death.
In physiologic conditions, TH controls cardiac
growth and maturation; its deficiency in the low
T3 syndrome is associated with alterations in
expression of TRs, contributing to the develop-
ment of a cardiac fetal phenotype, leading to car-
diac dysfunction.24–29
The hypoxia and the inflammatory response to
HF are able to reduce the type 2 deiodinase
activity in the cardiomyocytes, which results in a
decrease of intracellular T3 bioavailability.24
Changes in the deiodinase activities are associ-
ated with the increase in proinflammatory cyto-
kines; they can modulate the cardiac levels of
T3, contributing to a local low T3 state in the failing
heart. Hypoxia also is able to induce the expres-
sion of D3 in cardiomyocytes. In a rat model of
right ventricular (RV) hypertrophy and failure, D3
activity increased in the chronically overloaded
RV, whereas no changes were observed in the
LV of the same heart.25
The abnormalities in TRs and the decreased
deiodinase activities could both lead to the devel-
opment of important changes in cardiac geneexpression, which are similar to those observed
in hypothyroidism. The induction of D3 in the car-
diomyocytes is associated with a decrease in the
T3 concentrations in the tissue and in the T3-
dependent gene expression with TRa 1 overex-
pression.26–29 In a rat model of starvation-
induced low T3 syndrome, the mRNA content of
the a-MHC and SERCA2 was reduced.27,29,30
Propylthiouracil-induced hypothyroidism in rats
was responsible for a reduction of the myocyte
cross-sectional area, leading to cardiac atrophy.
Similarly, T3 deficiency induces alterations in the
myocyte shape typical of progressive HF.31,32
Therefore, long-term T3 deficiency is responsible
for the negative effects on myocardial function,
histology, and morphology, inducing cellular
fibrosis and a negative cardiac remodeling with
cellular and structural changes similar to those
observed in the progression of HF31,32 (Table 1).
All these findings suggest that T3 has an important
role in regulating myocyte transverse shape and
wall stress and could play a key role during the
progression of HF in patients with low T3
syndrome.24–32
Up to 30% of patients with HF have low serum
T3 levels; they are associated with CV changes in
humans. Although the a-MHC isoform is preva-
lently expressed in the human heart, changes in
the MHC isoform expression can occur in the hu-
man atria in patients with congestive HF and in se-
vere hypothyroidism.33,34 These changes also are
linked to a decreased expression of SERCA 2
and increased cytoskeletal abnormalities, with
consequent modifications in contractility, wall
stress, chamber diameters, and wall thickness.34
Studies in humans have demonstrated
that low serum T3 levels correlate with the severity
of HF when assessed by the New York Heart As-
sociation (NYHA) classification.35–37 Low T3
Biondi396syndrome occurs with a higher incidence in pa-
tients with NYHA classes III and IV compared
with NHYA I and NYHA II.34–37 In addition, the
negative prognostic role of the low T3 is enhanced
in patients with higher BNP concentration, both in
acute decompensated HF and chronic compen-
sated HF.37 The abnormal TH pattern in patients
with HF is associated with a high incidence of fatal
events. In a large cohort of cardiac patients with
ischemic HF and nonischemic HF, T3 levels and
left ventricular ejection fraction (LVEF) were the
only independent predictive variables of both car-
diac and cumulative deaths at multivariate anal-
ysis.36 Patients with low T3 levels and reduced
LVEF had the highest mortality compared with pa-
tients with similar LVEF but normal T3 levels.36
These results suggest that T3 levels can be useful
to identify patients at high risk for death.TREATMENT WITH THYROID HORMONES
Hypothyroid cardiac alterations in the failing heart
can be reversible with TH replacement therapy.
The T3 supplementation in the culture of neonatal
cardiomyocytes was associated with a positive
change in the myocyte shape, with an increased ra-
tio of the major to minor cell axis and an increase in
the synthesis of a-MHC.38–41 Treatment with phys-
iologic doses of T3 also normalized the SERCA2
contents of cardyomyocytes, improving systolic
and diastolic functions and heart performance.38–41
This Opinion is supported by the Following
consideration: (1) the evidence that T3 has positive
effects on the CV function, (2) the observation that
even mild TH deficiency is associated with a worse
outcome in cardiac patients, (3) the negative prog-
nostic impact of the low T3 syndrome, and (4) the
improvement of the cardiac dysfunction after TH
administration. On this basis, LT4, LT3, and TH an-
alogs have been administered to improve the
prognosis of patients with HF.
Some studies used LT4 in patients with HF
or dilated cardiomyopathy. Moruzzi and col-
leagues42,43 performed 2 randomized placebo-
controlled studies to evaluate the short-term and
long-term CV effects of oral LT4 at a dose of
0.1 mg per day. In both of these studies, LT4
was able to significantly improve cardiac contrac-
tility, resting LVEF, CO, and exercise capacity.42,43
Similar results were observed by Malik and col-
leagues,44 who administered intravenous LT4
(20 mg/h) in 10 consecutive patients with severe
systolic HF, which progressed to cardiogenic
shock. These patients had a significant improve-
ment in cardiac index, pulmonary capillary wedge
pressure, and mean arterial pressure after 24
hours and 36 hours of LT4 administration.The first study that used LT3 was performed by
Hamilton and colleagues.45 In a small nonrandom-
ized trial, these investigators used an intravenous
bolus of liothyronine (LT3) followed by LT3 infusion
in patients with advanced HF and low T3 syn-
drome.45 CO improved significantly 2 hours after
T3 administration. Moreover, SVR significantly
decreased without considerable changes in blood
pressure. Comparable findings were observed by
Pingitore and coworkers.46,47 They administered
physiologic doses of LT3 (20 mg/d/m2 body sur-
face) for a period of 96 hours in 6 patients with
advanced HF and low T3 syndrome.46 A progres-
sive reduction in SVR, an increase in LVEF, and
an improvement of CO were observed after T3
administration. These positive results were
confirmed in a placebo-controlled study by the
same investigators.47 They administered a 3-day
LT3 infusion in patients with chronic and stable
dilated cardiomyopathy and low T3 syndrome.
Their results showed an improved cardiac perfor-
mance and an increase in total cardiac work,
which were associated with a concomitant
improvement of the neuroendocrine pattern
(decreased noradrenaline plasma levels and N-ter-
minal prohormone of BNP).47
All these studies demonstrated that THs were
well tolerated with no occurrence of major or minor
side effects and without any increase in atrial ar-
rhythmias or heart rate.THYROID HORMONE ANALOGS IN HEART
FAILURE
3,5-diiodothyropropionic acid (DITPA), a TH
analog with a cardiac inotropic selectivity, was
tested in humans to treat congestive HF in a ran-
domized clinical trial.48 DITPA was able to improve
cardiac index and diastolic function and decrease
SVR; it also improved total cholesterol and LDL
cholesterol values and triglycerides. Its use, how-
ever, was not associated with an improvement of
CHF symptoms and generally was poorly tolerated
by the patients because of an average weight loss
of 11 kg. This decrease in weight was not related
to the gastrointestinal side effects, which were
common in patients treated with DITPA.48 DITPA
also suppressed the hypothalamic-pituitary-
thyroid axis and had a negative effect on bone
by increasing bone turnover.48 Unfortunately,
these several adverse events caused the with-
drawal of DITPA from clinical trials.SUMMARY
Large prospective multicenter studies are needed
to assess the usefulness of THs in treating and/or
The Management of Thyroid Abnormalities 397preventing the evolution of HF. Further research is
needed to establish which drugs (T3, T4, or ana-
logs) could be useful in treating patients with HF.
The timing of TH administration and the best
schedule for therapy (their dosage and route of
administration intravenous or orally) also should
be assessed.REFERENCES
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